Bayer-2026-JPM.pdf

1、44thAnnualJ.P.Morgan Healthcare ConferenceStefan OelrichMember Of The Board Of Management Of Bayer AGPresident PharmaceuticalsJanuary 13th,2026Driver for near-term growthFoundation for future growthCatalyst for improved performanceOur Strategy is Showing Tangible ResultsRenew toplineGrow pipeline va

2、lueNew InnovationModel yielding successFive new indications or products approved since last yearAdvanced or completed 16 clinical programs across phases in past yearAsundexian toplinedata announcedLeverage new operating modelMore focused and de-layered organizationIncreased performance and efficienc

3、y,while investing into future growthSustaining a mid-twenties margin despite LoEs44thAnnual J.P.Morgan Health Conference2Nubeqa and Kerendia withsustained growth momentum,offsetting Xarelto declinesNext wave of growthwith Beyonttra,Lynkuetand AsundexianRobust Eylea Franchiseand Foundational Business

4、Foundation for future growthCatalyst for improved performanceOur Strategy is Showing Tangible ResultsGrow pipeline valueNew InnovationModel yielding successFive new indications or products approved since last yearAdvanced or completed 16 clinical programs across phases in past yearAsundexian topline

5、data announcedLeverage new operating modelMore focused and de-layered organizationIncreased performance and efficiency,while investing into future growthSustaining a mid-twenties margin despite LoEs44thAnnual J.P.Morgan Health Conference3Driver for near-term growthRenew toplineNubeqa and Kerendia wi

6、thsustained growth momentum,offsetting Xarelto declinesNext wave of growthwith Beyonttra,Lynkuetand AsundexianRobust Eylea Franchiseand Foundational BusinessPharmaceuticals to Deliver on Raised 2025 Guidance44thAnnual J.P.Morgan Health Conference49M2025 ActualFY 2025 Guidanceat constant FX12025Estim